reference/15371365

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15371365

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	3087
issn	1529-0131 0004-3591
issueIdentifier	10
pageRange	3077-3087
publicationName	Arthritis and rheumatism
startingPage	3077
bibliographicCitation	Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct;62(10):3077–87. doi: 10.1002/art.27601. PMID: 20533545.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_535c72edb9063d501f36a215c554975a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_19f5ae360895d9dc71a19d4df778f5a8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc842dde82d4cecfe0fce885553758e2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0b48963bbe5cfee0d01058b1908fe7ab http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_850a08dea9d425e1c0e7a276fca93b18 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9eb6fced44634c3e0584fd51430f8a4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a722d2eaf3fabcc580dccefa2dc997ff http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7d325609ce6998f762732b87ace5097d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_19a40ca5c02c9a3f11c7ae859f66dbdc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_39328d788e333e3b3fce2a9e09c2c273 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2bd754178353777c0856d28a7272d018 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8d85ff2f5fe59164b0d0bc7544f877b8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db35d3409fbace6e833fc82550287fd3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9cb00ba9bceed1737ee0f7be1987fb05 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_20a0d16937d7fafcb8fdef118c36d6a0
date	2010-06-08^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1002/art.27601 https://pubmed.ncbi.nlm.nih.gov/20533545
isPartOf	https://portal.issn.org/resource/ISSN/1529-0131 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/881 https://portal.issn.org/resource/ISSN/0004-3591
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial
discusses	http://id.nlm.nih.gov/mesh/M0016932 http://id.nlm.nih.gov/mesh/M0442852 http://id.nlm.nih.gov/mesh/M0028142
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D018796Q000627 http://id.nlm.nih.gov/mesh/D008180Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D057194 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000069594 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D010919
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8841 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9251 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6965 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8902 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8370 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8548

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275

Showing number of triples: 1 to 57 of 57.